Reports that Erin Patterson, a woman convicted of a triple murder, has been approved for taxpayer-funded Ozempic injections while incarcerated have ignited a firestorm of public criticism. The news has drawn sharp condemnation from various figures and the public alike, questioning the allocation of public funds for such treatments within the prison system.
Controversy Surrounds Inmate’s Access to Weight-Loss Medication
Erin Patterson, 51, is currently serving a life sentence at the Dame Phyllis Frost Centre in Melbourne, a maximum-security facility. She was found guilty of murdering her in-laws, Don and Gail Patterson, and Gail’s sister, Heather Wilkinson, after they consumed death cap mushrooms at her home in July 2023. Heather’s husband, Ian Wilkinson, survived the poisoning but became critically ill, and Patterson was also convicted of his attempted murder. Due to the high-profile nature of her trial, Patterson has been held in isolation for extended periods.
The decision to approve Ozempic for Patterson, reportedly due to her being “isolated and unable to exercise,” has been met with disbelief. A source within the prison system reportedly told the Herald Sun, “Staff safety is a huge concern, yet management appear more concerned about the weight of a convicted killer.”
Public Figures Voice Strong Opposition
Australian actress Madeleine West has been a prominent voice in the public outcry. She shared a news article detailing the situation, expressing her dismay. “This is Australia,” West stated, accompanying her post with an angry emoji. “While Australian families are doing it tough, convicted murderers are getting taxpayer-funded cosmetic medication and convicted child predators are getting NDIS funding.” Her comments highlight a broader public sentiment that resources should be prioritized for struggling families and essential services rather than inmate treatments perceived as non-essential.
The cost of Ozempic, while subsidized for eligible patients with type 2 diabetes to around $25 per month, still represents a public expense. Unsubsidized alternatives for weight loss can range from $285 to $700 monthly. This financial aspect has further fueled public anger, with many questioning the justification for using taxpayer money on such treatments for individuals convicted of serious crimes.
Official Justification for Inmate Medical Treatments
A spokesperson for the Department of Justice and Community Safety stated that inmates’ access to weight loss drugs is determined by medical advice. “Prescriptions are only given by clinicians when there’s a clear medical need – like preventing serious conditions such as type 2 diabetes,” the spokesperson explained. This suggests that such treatments are intended to address underlying health issues rather than purely cosmetic concerns.
During her lengthy trial, Patterson herself spoke about her lifelong struggles with binge eating and body image issues. These personal revelations emerged as she explained her actions following the fatal meal, including consuming cake before becoming ill herself. Patterson has consistently maintained her innocence and is currently awaiting a decision on her appeal against her conviction, which cited grounds including a “substantial miscarriage of justice” and the exclusion of mushroom-related evidence.
Precedent of Inmates Receiving Ozempic
Patterson is not the first inmate to be approved for Ozempic while in prison. Alicia Schiller, serving a 16-year sentence for murder, has also reportedly been granted access to the drug. Schiller, who killed her housemate in 2014, was reportedly prescribed Ozempic after gaining weight in prison. Reports indicated she had turned her cell into a “candy shop” and frequently consumed sweets and soft drinks. Her victim’s mother expressed outrage, calling the situation “absolutely ridiculous” and a waste of public funds, suggesting that Schiller should first be restricted from consuming sweets.
Minister Nick Staikos has previously defended the use of weight loss injections for inmates, framing it as a matter of preventing serious illness. “Prevention and preventing serious illness, actually will save the taxpayer in the long run,” he stated, emphasizing that such decisions are made by clinicians based on medical necessity rather than personal sympathy for the inmate.
Ongoing Legal Proceedings and Public Reaction
The Director of Public Prosecutions has also appealed Patterson’s sentence, arguing it was too lenient and seeking a full life sentence without parole. The outcome of these appeals, along with the ongoing debate surrounding inmate healthcare and resource allocation, continues to be a significant point of public interest and contention.
The case raises complex questions about the balance between providing necessary medical care to all individuals, regardless of their criminal status, and managing public funds responsibly. While the Department of Justice emphasizes medical necessity, the public perception, fueled by high-profile cases and the severity of the crimes committed, remains largely critical.
